What we are learning about CLL treatments and the microenvironment
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Choosing treatment options for CLL and combining novel drugs
Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt
Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian